Abstract
Background People of South Asian and African Caribbean ethnicities living in UK have a high risk of cardiometabolic disease. Limited data exist regarding detailed cardiometabolic phenotyping in this population. Methods enabling this are widely available, but the practical aspects of undertaking such studies in large and diverse samples are seldom reported.
Methods The Southall and Brent Revisited (SABRE) study is the UK’s largest tri-ethnic longitudinal cohort. Over 1400 surviving participants (58-85 y) attended the 2nd study-visit (2008-2011) during which comprehensive cardiovascular phenotyping, including 3D-echocardiography (3D-speckle-tracking (3D-STE)), computed tomography, coronary artery calcium scoring, pulse-wave velocity, central blood pressure, carotid artery ultrasound and retinal imaging were performed. We describe the methods used with the aim of providing a guide to their feasibility and reproducibility in a large tri-ethnic population-based study of older people.
Results Conventional echocardiography and all vascular measurements showed high feasibility (>90% analyzable of clinic-attendees). 3DE and 3D-STE were less feasible in this age group (76% 3DE acquisition feasibility and 38% 3D-STE feasibility of clinic-attendees). Intra- and inter-observer variabilities were excellent for most of conventional and advanced echocardiographic measures. The test-retest reproducibility was good-excellent and fair-good for conventional and advanced echocardiographic measures, respectively, but lower than when re-reading the same images. All vascular measures demonstrated excellent or fair-good reproducibility.
Conclusions Detailed cardiovascular phenotyping is feasible and reproducible in an ethnically diverse population. The data collected will lead to a better understanding of why people of South Asian and African Caribbean ancestry are at elevated risk of cardiometabolic diseases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Southall study was supported by the UK Medical Research Council (MRC), the British Diabetic Association (now Diabetes UK), the Wellcome Trust and British Heart Foundation (BHF). The Brent study was supported by the UK MRC. The main SABRE study is supported by the Wellcome Trust (082464) and BHF (SP/07/001/23603, CS/13/1/30327). The SABRE Cognitive function substudy was funded by the Wellcome Trust (089056), and the SABRE 3D Heart substudy was funded by the BHF (PG08 103). The SABRE metabolomics substudy was funded by Diabetes UK (13/0004774).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by St Mary Hospital Local Research Ethics Committee(07/H0712/109).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data underlying this article are available in the article and in its online supplementary material.